On March 10, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which will be held virtually from April 10-15, 2021 (Press release, Curis, MAR 10, 2021, View Source [SID1234576439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Poster Presentation

Title: Identification of NF-kappaB phospho-p50 as a Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in Patients with Non-Hodgkin’s Lymphoma
Session Name: Biomarkers Predictive of Therapeutic Benefit
Session Date: Saturday, April 10, 2021
Additional meeting information can be found on the AACR (Free AACR Whitepaper) website View Source The presentation will also be available under "Events and Presentations" in the Investors section of the Company’s website at www.curis.com.